Gastro-esophageal CancerNCT05650827
Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer
A study testing Resistance training and Protein supplement in people with Gastro-esophageal Cancer, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
Trial summary
Patients with advanced gastroesophageal cancer are in great risk of losing skeletal muscle mass and developing cancer cachexia. Low skeletal muscle mass has a negative impact on quality of life, impairs physical function, increases toxicity from anti-neoplastic treatment, as well as increases risk of death. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastro-esophageal Cancer
- What is being tested?
- Resistance training and Protein supplement
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteDenmark
- Study dates
- 24 Feb 2023to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- histologically verified, non-resectable cancer of the esophagus, stomach, or gastroesophageal junction
- referred to first line chemotherapy.
Who cannot join
- Age < 18
- Living outside the greater Copenhagen area
- Any other malignancy requiring active treatment
- Not eligible for chemotherapy
- Performance status > 2
- Not able to swallow liquids
Show all 10Show fewer
- Parenteral nutrition or enteral nutrition via feeding tube
- Physical or mental disabilities that prohibit execution of test or training procedures
- Pregnancy
- Inability to understand the Danish language
Trial locations and contacts
1 site in 1 country.
About this study
Patients with advanced gastroesophageal cancer are in great risk of losing skeletal muscle mass and developing cancer cachexia. Low skeletal muscle mass has a negative impact on quality of life, impairs physical function, increases toxicity from anti-neoplastic treatment, as well as increases risk of death.
Resistance training and protein supplements have the potential to stimulate muscle anabolism and counteract loss of skeletal muscle mass. Therefore, the investigators have designed a randomized controlled feasibility trial to evaluate the feasibility, safety and the therapeutic effect of resistance training and protein supplements in patients with advanced gastroesophageal cancer undergoing first line chemotherapy.
A total of 54 patients with advanced gastroesophageal cancer will be recruited from the Department of Oncology, Copenhagen University Hospital, Rigshospitalet and randomly allocated 2:1 to standard care plus resistance training 3 times pr. week and a daily supplement of protein or to standard care alone.
- Conditions
- Gastro-esophageal Cancer
- Being tested
- Resistance training, Protein supplement
- Keywords
- Exercise oncology, Resistance exercise, Cancer, Cancer cachexia, Protein supplements, Sarcopenia, Palliative chemotherapy
- Medical subject headings
- Neoplasms, Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resistance trainingBehavioural
10 weeks of resistance training 3 times pr. week.
Protein supplementDietary supplement
A daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight
| Study group | Role | What they receive |
|---|---|---|
| Standard Care Control | No intervention | Participants allocated to control receive first line chemotherapy the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark. Participants allocated to control are allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise training program. There will be no diet restrictions. |
| Exercise and protein supplements intervention group | Experimental | Participants allocated to intervention receive first line chemotherapy and the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark.
The intervention consists of resistance training and a daily protein supplement. Receives: Behavioral: Resistance training; Dietary Supplement: Protein supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Exercise feasibility: Exercise sessions attendance
The number of attended exercise training sessions relative to the number of planed exercise sessions
Measured: From baseline until end of intervention (10 weeks)
Exercise feasibility: Relative dose-intensity of protein supplement
The actual amount consumed relative to the amount prescribed over the intervention period
Measured: From baseline until end of intervention (10 weeks)
Incidence of Serious Adverse Events (SAEs).
SAE will be recorded during trial assessment visits and through medical records. This procedure will concern any SAE during the trial period. For each trial visit we will collect patients' self-report of SAEs, which may have occurred during the period since the last trial visit.
Measured: Baseline until end of intervention (10 weeks)
Secondary outcomes (53)
Exercise feasibility: Relative dose intensity of exercise
The actual dose relative to the prescribed minimum dose
Measured: Baseline until end of intervention (10 weeks)
Exercise feasibility: Early termination of exercise sessions
Termination of an exercise session before the prescribed exercises have been performed
Measured: Baseline until end of intervention (10 weeks)
Exercise feasibility: Exercise intervention interruptions
Incidence of exercise intervention disruptions, defined as a period of ≥ 7 days without an attended exercise session
Measured: Baseline until end of intervention (10 weeks)
Exercise feasibility: Permanent discontinuation
Incidence of permanent withdrawal from the intervention before intervention period has ended.
Measured: Baseline until end of intervention (10 weeks)
Body composition and anthropometrics: Total lean mass
Changes in total lean mass, assessed by dual energy x-ray absorptiometry (DXA)
Measured: Baseline, end of week 10
Body composition and anthropometrics: Appendicular lean mass
Changes in appendicular lean mass, assessed by DXA
Measured: Baseline, end of week 10
Body composition and anthropometrics: Total fat mass
Changes in total fat mass, assessed by DXA
Measured: Baseline, end of week 10
Body composition and anthropometrics: Fat percentage
Changes in fat percentage, assessed by DXA
Measured: Baseline, end of week 10
Body composition and anthropometrics: Bone mineral density
Changes in bone mineral density, assessed by DXA
Measured: Baseline, end of week 10
Body composition and anthropometrics: Muscle thickness
Changes in thickness of the vastus lateralis, assessed by ultrasound
Measured: Baseline, end of week 10
Body composition and anthropometrics: Skeletal muscle index
Changes in skeletal muscle index, assessed by diagnostic CT scans
Measured: At diagnose, after 10 weeks intervention and at 1 year follow up
Body composition and anthropometrics: Skeletal muscle attenuation
Changes in skeletal muscle attenuation, assessed by diagnostic CT scans
Measured: At diagnose, end of week 10
Body composition and anthropometrics: Adipose tissue index
Changes in adipose tissue index, assessed by diagnostic CT scans
Measured: At diagnose, end of week 10
Body composition and anthropometrics: Body mass
Changes in body mass
Measured: Baseline, end of week 10
Body composition and anthropometrics: Body mass index
Changes in body mass index
Measured: Baseline, end of week 10
Body composition and anthropometrics: Hip circumference
Changes in hip circumference
Measured: Baseline, end of week 10
Body composition and anthropometrics: Waist circumference
Changes in waist circumference
Measured: Baseline, end of week 10
Muscle strength: Leg press maximal muscle strenght
Changes in leg press one repetition maximum (1RM)
Measured: Baseline, end of week 10
Muscle strength: Chest press maximal muscle strenght
Changes in chest press 1RM
Measured: Baseline, end of week 10
Muscle strength: Hand grip strenght
Changes in hand grip strength, assessed using a dynamometer
Measured: Baseline, end of week 10
Functional performance: Habituel gait speed
Changes in habitual gait speed
Measured: Baseline, end of week 10
Functional performance: Maximal gait speed
Changes in maximal gait speed
Measured: Baseline, end of week 10
Functional performance: Sit-to-stand
Changes in sit-to-stand power.
Measured: Baseline, end of week 10
Functional performance: Stair climb
Changes in stair climbing power
Measured: Baseline, end of week 10
Resting metabolic rate
Changes in resting metabolic rate
Measured: Baseline, end of week 10
Blood pressure: Systolic blood pressure
Changes in systolic blood pressure
Measured: Baseline, end of week 10
Blood pressure: Diastolic blood pressure
Changes in diastolic blood pressure
Measured: Baseline, end of week 10
Heart rate
Changes in resting heart rate
Measured: Baseline, end of week 10
1 and 2-years cancer-specific survival
Proportion of patients who have not died from gastroesophageal cancer 1 and 2 years after randomization
Measured: Randomization to 1 and 2 years after randomization
1 and 2-years over-all survival
Proportion of patients who have not died 1 and 2 years after randomization
Measured: Randomization to 1 and 2 years after randomization
Progression-free survival
Time to progression
Measured: Randomization to 2 years after randomization
Treatment tolerance: Hospitalization
Unscheduled hospitalization
Measured: 3, 6 and 9 weeks after randomization
Treatment tolerance: Relative dose intensity
Treatment tolerance assessed by the delivery of chemotherapy (relative dose intensity)
Measured: 3, 6 and 9 weeks after randomization
Treatment tolerance: Number of series recieved
Treatment tolerance assessed by the delivery of chemotherapy (number of series recieved)
Measured: 3, 6 and 9 weeks after randomization
Treatment tolerance: Tolerated dose
Treatment tolerance assessed by the delivery of chemotherapy (dose reduction)
Measured: 3, 6 and 9 weeks after randomization
Treatment tolerance: Permanent discontinuation of the treatment
Treatment tolerance assessed by the delivery of chemotherapy (permanent discontinuation of the treatment)
Measured: 3, 6 and 9 weeks after randomization
Treatment effect: Response to chemotherapy
Response to chemotherapy assessed by Response Evaluation Criteria in Solid Tumors 1.1 (complete response, partiel response, stable disease, progressive disease)
Measured: Randomization to 2 years after randomization
Health-related quality of life: Physical well-being
Changes in patient-reported physical well-being assessed using the Functional Assessment of Cancer Therapy - Esophagus (FACT-E) (scale-scoring 0-28, the higher the score the better quality of life)
Measured: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Health-related quality of life: Social well-being
Changes in patient-reported social well-being assessed using FACT-E (scale-scoring 0-28, the higher the score the better quality of life)
Measured: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Health-related quality of life: Emotional well-being
Changes in patient-reported social well-being assessed using FACT-E (scale-scoring 0-24, the higher the score the better quality of life)
Measured: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Health-related quality of life: Functional well-being
Changes in patient-reported functional well-being assessed using FACT-E (scale-scoring 0-28, the higher the score the better quality of life)
Measured: Baseline,10 weeks-, 1 year-, 2 years after randomization
Health-related quality of life: gastroesophageal cancer specific
Changes in patient-reported gastroesophageal cancer specific well-being assessed using FACT-E (scale-scoring 0-68, the higher the score the better quality of life)
Measured: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Health-related quality of life: cancer cachexia specific
Changes in patient-reported cancer cachexia specific well-being assessed using Functional Assessment of Cancer Therapy - Cancer Cachexia (scale-scoring 0-48, the higher the score the better quality of life)
Measured: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Depression
Changes in patient-reported depression, assessed using the Hospital Anxiety and Depression Scale (HADS) (scale scoring: 0-21, the higher the score the worse the condition)
Measured: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Anxiety
Changes in patient-reported anxiety, assessed using the HADS (scale scoring: 0-21, the higher the score the worse the condition)
Measured: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Self-reported physical activity: Walking
Changes in patient-reported weekly duration of walking, assessed using the International Physical Activity Questionnaire (IPAQ)
Measured: Baseline, end of week 10
Self-reported physical activity: Moderate intensity physical activity (PA)
Changes in patient-reported weekly duration of moderate intensity PA, assessed using the IPAQ
Measured: Baseline, end of week 10
Self-reported physical activity: Vigorous intensity PA
Changes in patient-reported weekly duration of vigorous intensity PA, assessed using the IPAQ
Measured: Baseline, end of week 10
Self-reported physical activity: Total PA
Changes in patient-reported weekly duration of total PA, assessed using the IPAQ (Expressed as metabolic equivalent (MET)-min per week: MET level x minutes of activity x events per week)
Measured: Baseline, end of week 10
Self-reported physical activity: Sitting time
Changes in patient-reported weekly duration of sitting time, assessed using the IPAQ
Measured: Baseline, end of week 10
Self-reported screening of sarcopenia
Changes in patient-reported signs of sarcopenia, assessed using The Strength, assistance in walking, rise from a chair, climb stairs, and falls (SARC-F) questionnaire (scale scoring: 0-10, the higher the score the better the condition)
Measured: Baseline, end of week 10
Self-reported three-days dietary records
Changes in patient-reported three-day record of dietary intake assessed using questionnaries.
Measured: Baseline, week 5 and week 10
Patient-reported symptomatic adverse events
Patient-reported symptomatic adverse events, assessed using the using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Measured: One week after each serie of chemotherapy during the intervention (10 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Dec 2022
- Study start24 Feb 2023
- Primary completion31 Dec 2024
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gastro-esophageal CancerStudies of the same condition, open and under way.
- More trials run by Copenhagen University Hospital, RigshospitaletThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 54 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rikke Krabek, MD, Copenhagen University Hospital, Rigshospitalet
- Investigators
- Casper Simonsen, PhD, Principal investigator, Copenhagen University Hospital, Rigshospitalet, Denmark
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05650827
- Sponsor's protocol ID
- 18.10.22
- Status last verified
- May 2025
- First submitted
- 2 Dec 2022
- Last updated
- 14 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Krabek R, Kristensen KB, Thomsen SN, Sorensen AH, Christensen PL, Pedersen KC, Rytter A, Dieli-Conwright CM, Suetta C, Sylow L, Pedersen BK, Mau-Sorensen M, Simonsen C. Resistance training and protein supplementation in patients with incurable gastroesophageal cancer: a randomized feasibility trial. Support Care Cancer. 2026 Nov 5;34(11):1194. doi: 10.1007/s00520-026-11430-2.
PubMed 42982936
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer
- ClinicalTrials.gov ID
- NCT05650827
- Acronym / sponsor ID
- 18.10.22
- Conditions
- Gastro-esophageal Cancer
- Keywords
- Exercise oncology, Resistance exercise, Cancer, Cancer cachexia, Protein supplements, Sarcopenia, Palliative chemotherapy
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 54 participants (estimated)
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletUniversity, hospital or other
- Study start
- 24 Feb 2023 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 14 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with advanced gastroesophageal cancer are in great risk of losing skeletal muscle mass and developing cancer cachexia. Low skeletal muscle mass has a negative impact on quality of life, impairs physical function, increases toxicity from anti-neoplastic treatment, as well as increases risk of death.
Resistance training and protein supplements have the potential to stimulate muscle anabolism and counteract loss of skeletal muscle mass. Therefore, the investigators have designed a randomized controlled feasibility trial to evaluate the feasibility, safety and the therapeutic effect of resistance training and protein supplements in patients with advanced gastroesophageal cancer undergoing first line chemotherapy.
A total of 54 patients with advanced gastroesophageal cancer will be recruited from the Department of Oncology, Copenhagen University Hospital, Rigshospitalet and randomly allocated 2:1 to standard care plus resistance training 3 times pr. week and a daily supplement of protein or to standard care alone.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard Care Control | No intervention | –Participants allocated to control receive first line chemotherapy the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark. Participants allocated to control are allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise training program. There will be no diet restrictions. |
| Exercise and protein supplements intervention group | Experimental | Behavioral: Resistance training, Dietary Supplement: Protein supplementParticipants allocated to intervention receive first line chemotherapy and the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark. The intervention consists of resistance training and a daily protein supplement. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- histologically verified, non-resectable cancer of the esophagus, stomach, or gastroesophageal junction
- referred to first line chemotherapy.
Key exclusion criteria (10 listed)
- Age < 18
- Living outside the greater Copenhagen area
- Any other malignancy requiring active treatment
- Not eligible for chemotherapy
- Performance status > 2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resistance training10 weeks of resistance training 3 times pr. week. | Behavioural | Exercise and protein supplements intervention group |
| Protein supplementA daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight | Dietary supplement | Exercise and protein supplements intervention group |
Primary outcome
Exercise feasibility: Exercise sessions attendance
Time frame: From baseline until end of intervention (10 weeks)
The number of attended exercise training sessions relative to the number of planed exercise sessions
Exercise feasibility: Relative dose-intensity of protein supplement
Time frame: From baseline until end of intervention (10 weeks)
The actual amount consumed relative to the amount prescribed over the intervention period
Incidence of Serious Adverse Events (SAEs).
Time frame: Baseline until end of intervention (10 weeks)
SAE will be recorded during trial assessment visits and through medical records. This procedure will concern any SAE during the trial period. For each trial visit we will collect patients' self-report of SAEs, which may have occurred during the period since the last trial visit.
53 secondary outcomes
Exercise feasibility: Relative dose intensity of exercise
Time frame: Baseline until end of intervention (10 weeks)
Exercise feasibility: Early termination of exercise sessions
Time frame: Baseline until end of intervention (10 weeks)
Exercise feasibility: Exercise intervention interruptions
Time frame: Baseline until end of intervention (10 weeks)
Exercise feasibility: Permanent discontinuation
Time frame: Baseline until end of intervention (10 weeks)
Body composition and anthropometrics: Total lean mass
Time frame: Baseline, end of week 10
Body composition and anthropometrics: Appendicular lean mass
Time frame: Baseline, end of week 10
Body composition and anthropometrics: Total fat mass
Time frame: Baseline, end of week 10
Body composition and anthropometrics: Fat percentage
Time frame: Baseline, end of week 10
Body composition and anthropometrics: Bone mineral density
Time frame: Baseline, end of week 10
Body composition and anthropometrics: Muscle thickness
Time frame: Baseline, end of week 10
Body composition and anthropometrics: Skeletal muscle index
Time frame: At diagnose, after 10 weeks intervention and at 1 year follow up
Body composition and anthropometrics: Skeletal muscle attenuation
Time frame: At diagnose, end of week 10
Body composition and anthropometrics: Adipose tissue index
Time frame: At diagnose, end of week 10
Body composition and anthropometrics: Body mass
Time frame: Baseline, end of week 10
Body composition and anthropometrics: Body mass index
Time frame: Baseline, end of week 10
Body composition and anthropometrics: Hip circumference
Time frame: Baseline, end of week 10
Body composition and anthropometrics: Waist circumference
Time frame: Baseline, end of week 10
Muscle strength: Leg press maximal muscle strenght
Time frame: Baseline, end of week 10
Muscle strength: Chest press maximal muscle strenght
Time frame: Baseline, end of week 10
Muscle strength: Hand grip strenght
Time frame: Baseline, end of week 10
Functional performance: Habituel gait speed
Time frame: Baseline, end of week 10
Functional performance: Maximal gait speed
Time frame: Baseline, end of week 10
Functional performance: Sit-to-stand
Time frame: Baseline, end of week 10
Functional performance: Stair climb
Time frame: Baseline, end of week 10
Resting metabolic rate
Time frame: Baseline, end of week 10
Blood pressure: Systolic blood pressure
Time frame: Baseline, end of week 10
Blood pressure: Diastolic blood pressure
Time frame: Baseline, end of week 10
Heart rate
Time frame: Baseline, end of week 10
1 and 2-years cancer-specific survival
Time frame: Randomization to 1 and 2 years after randomization
1 and 2-years over-all survival
Time frame: Randomization to 1 and 2 years after randomization
Progression-free survival
Time frame: Randomization to 2 years after randomization
Treatment tolerance: Hospitalization
Time frame: 3, 6 and 9 weeks after randomization
Treatment tolerance: Relative dose intensity
Time frame: 3, 6 and 9 weeks after randomization
Treatment tolerance: Number of series recieved
Time frame: 3, 6 and 9 weeks after randomization
Treatment tolerance: Tolerated dose
Time frame: 3, 6 and 9 weeks after randomization
Treatment tolerance: Permanent discontinuation of the treatment
Time frame: 3, 6 and 9 weeks after randomization
Treatment effect: Response to chemotherapy
Time frame: Randomization to 2 years after randomization
Health-related quality of life: Physical well-being
Time frame: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Health-related quality of life: Social well-being
Time frame: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Health-related quality of life: Emotional well-being
Time frame: Baseline, 10 weeks-, 1 year-, and 2 years after randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2025.
- Derived from this study: PubMed 42982936Krabek R, Kristensen KB, Thomsen SN, Sorensen AH, Christensen PL, Pedersen KC, Rytter A, Dieli-Conwright CM, Suetta C, Sylow L, Pedersen BK, Mau-Sorensen M, Simonsen C. Resistance training and protein supplementation in patients with incurable gastroesophageal cancer: a randomized feasibility trial. Support Care Cancer. 2026 Nov 5;34(11):1194. doi: 10.1007/s00520-026-11430-2.
- Individual participant dataSharing planned: No
Related trials for Gastro-esophageal Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 2
Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Stomach Neoplasms
RecruitingPhase 1/2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Casper Simonsen, PhD principal investigator
Copenhagen University Hospital, Rigshospitalet, Denmark
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resistance training and Protein supplement in people with Gastro-esophageal Cancer, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exercise feasibility: Exercise sessions attendance (time frame: From baseline until end of intervention (10 weeks)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05650827, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2025.